Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)
Mineralys Therapeutics (MLYS) reported Research & Development of $221.38 million for Q2 2026, up 478.3% from $38.28 million a year earlier and up 808.6% from the prior quarter.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Mineralys Therapeutics' Research & Development came in at $301.59 million, up 72.6% year-over-year; for FY2025, it was $132.01 million, down 21.7% from FY2024.
- Research & Development has a three-year compound annual growth rate of 71.3% (FY2022 to FY2025).
- By year, Research & Development came in at $168.58 million in FY2024 (+139.6%), $70.36 million in FY2023 (+168.0%) and $26.25 million in FY2022.
- The Q2 2026 figure ranks as the highest quarterly Research & Development in data going back to Q1 2022.
- Year over year, Research & Development gained in four of the last eight quarters, with growth averaging 75.6%.
- The high point for year-over-year Research & Development in five years was Q2 2026 (growth of 478.3%); the low point was Q4 2025 (a decline of 45.2%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $24.37 million (Q1 2026), $24.4 million (Q4 2025) and $31.45 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Mineralys Therapeutics | 2.26 Bn | 2.26 Bn | - | 221.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 221.38 Mn |
| Mar 31, 2026 | 24.37 Mn |
| Dec 31, 2025 | 24.40 Mn |
| Sep 30, 2025 | 31.45 Mn |
| Jun 30, 2025 | 38.28 Mn |
| Mar 31, 2025 | 37.88 Mn |
| Dec 31, 2024 | 44.57 Mn |
| Sep 30, 2024 | 53.99 Mn |
| Jun 30, 2024 | 39.27 Mn |
| Mar 31, 2024 | 30.75 Mn |
| Dec 31, 2023 | 23.69 Mn |
| Sep 30, 2023 | 22.50 Mn |
| Jun 30, 2023 | 11.88 Mn |
| Mar 31, 2023 | 12.29 Mn |
| Dec 31, 2022 | 7.82 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 6.78 Mn |
API Access
Mineralys Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();